- Home
- RNAZ vs NEUP Comparison
RNAZ vs NEUP Comparison
Compare RNAZ & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- NEUP
- Stock Information
- Founded
- RNAZ 2016
- NEUP 1996
- Country
- RNAZ United States
- NEUP United States
- Employees
- RNAZ N/A
- NEUP N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- RNAZ Health Care
- NEUP
- Exchange
- RNAZ Nasdaq
- NEUP Nasdaq
- Market Cap
- RNAZ 4.9M
- NEUP 5.5M
- IPO Year
- RNAZ 2021
- NEUP N/A
- Fundamental
- Price
- RNAZ $3.35
- NEUP $3.15
- Analyst Decision
- RNAZ Strong Buy
- NEUP
- Analyst Count
- RNAZ 1
- NEUP 0
- Target Price
- RNAZ $20.00
- NEUP N/A
- AVG Volume (30 Days)
- RNAZ 143.7K
- NEUP 625.4K
- Earning Date
- RNAZ 11-14-2024
- NEUP 02-13-2025
- Dividend Yield
- RNAZ N/A
- NEUP N/A
- EPS Growth
- RNAZ N/A
- NEUP N/A
- EPS
- RNAZ N/A
- NEUP N/A
- Revenue
- RNAZ N/A
- NEUP N/A
- Revenue This Year
- RNAZ N/A
- NEUP N/A
- Revenue Next Year
- RNAZ N/A
- NEUP N/A
- P/E Ratio
- RNAZ N/A
- NEUP N/A
- Revenue Growth
- RNAZ N/A
- NEUP N/A
- 52 Week Low
- RNAZ $2.66
- NEUP $2.12
- 52 Week High
- RNAZ $66.33
- NEUP $16.08
- Technical
- Relative Strength Index (RSI)
- RNAZ 30.32
- NEUP N/A
- Support Level
- RNAZ $2.90
- NEUP N/A
- Resistance Level
- RNAZ $3.50
- NEUP N/A
- Average True Range (ATR)
- RNAZ 0.42
- NEUP 0.00
- MACD
- RNAZ 0.31
- NEUP 0.00
- Stochastic Oscillator
- RNAZ 50.74
- NEUP 0.00
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.